Literature DB >> 1823868

Metabolism of carvedilol in man.

G Neugebauer1, P Neubert.   

Abstract

The metabolism of carvedilol was investigated in plasma and urine of 3 healthy male volunteers after administration of 50 mg of [14C]-labelled drug. Rapid and extensive biotransformation occurred. After 1.5 h 9% of total radioactivity in plasma consisted of unchanged drug, 22% of carvedilol-glucuronide and another 20% of oxidative cleavage products of the beta-blocking side chain. Urinary excretion of radioactivity amounted to 16% of which 2% represented unchanged drug, 32% carvedilol-glucuronide and about 25% side chain oxidation products. Ring-hydroxylated metabolites of carvedilol accounted for 18% of the radioactive compounds in the urine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1823868     DOI: 10.1007/BF03189969

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  2 in total

1.  Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker.

Authors:  E von Möllendorff; K Reiff; G Neugebauer
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Clinical pharmacologic investigations with carvedilol, a new beta-blocker with direct vasodilator activity.

Authors:  E von Möllendorff; U Abshagen; W Akpan; G Neugebauer; E Schröter
Journal:  Clin Pharmacol Ther       Date:  1986-06       Impact factor: 6.875

  2 in total
  14 in total

1.  Novel carvedilol analogues that suppress store-overload-induced Ca2+ release.

Authors:  Chris D Smith; Aixia Wang; Kannan Vembaiyan; Jingqun Zhang; Cuihong Xie; Qiang Zhou; Guogen Wu; S R Wayne Chen; Thomas G Back
Journal:  J Med Chem       Date:  2013-11-05       Impact factor: 7.446

2.  The role of CYP2C9 genetic polymorphism in carvedilol O-desmethylation in vitro.

Authors:  Pei-Pei Pan; Qing-Hua Weng; Chen-Jian Zhou; Yan-Li Wei; Li Wang; Da-Peng Dai; Jian-Ping Cai; Guo-Xin Hu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-12-05       Impact factor: 2.441

3.  New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics.

Authors:  Joost Bart; Eli C F Dijkers; Theodora D Wegman; Elisabeth G E de Vries; Winette T A van der Graaf; Harry J M Groen; Willem Vaalburg; Antoon T M Willemsen; N Harry Hendrikse
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

Review 4.  Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  C J Dunn; A P Lea; A J Wagstaff
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 5.  Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain.

Authors:  Philip H Elsinga; N Harry Hendrikse; Joost Bart; Aren van Waarde; Willem Vaalburg
Journal:  Mol Imaging Biol       Date:  2005 Jan-Feb       Impact factor: 3.488

Review 6.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

7.  Stereoselective glucuronidation of carvedilol by Chinese liver microsomes.

Authors:  Lin-ya You; Chun-na Yu; Sheng-gu Xie; Shu-qing Chen; Su Zeng
Journal:  J Zhejiang Univ Sci B       Date:  2007-10       Impact factor: 3.066

Review 8.  Chronic heart failure: beta-blockers and pharmacogenetics.

Authors:  Junichi Azuma; Shinpei Nonen
Journal:  Eur J Clin Pharmacol       Date:  2008-10-07       Impact factor: 2.953

Review 9.  Clinical pharmacokinetics and pharmacodynamics of carvedilol.

Authors:  T Morgan
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

10.  Comparison of free-radical inhibiting antioxidant properties of carvedilol and its phenolic metabolites.

Authors:  Thomas C Malig; Mitchell R Ashkin; Austin L Burman; Manuel Barday; Belinda J M Heyne; Thomas G Back
Journal:  Medchemcomm       Date:  2017-01-30       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.